The experimental drug, rentosertib, comes from Insilico Medicine and was developed to treat idiopathic pulmonary fibrosis, a disease that progressively scars the lungs.

Insilico Medicine's AI-discovered drug rentosertib enters Phase III trials for lung fibrosis, targeting cellular senescence with implications for

Six proteomic ageing clocks agreed patients on Insilico’s AI-designed lung drug looked younger. The authors cannot yet rule out the treated lung.